Metabolism of a G Protein-Coupled Receptor Modulator, Including Two Major 1,2,4-Oxadiazole Ring-Opened Metabolites and a Rearranged Cysteine-Piperazine Adduct
- 7 March 2012
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 40 (6), 1151-1163
- https://doi.org/10.1124/dmd.112.044636
Abstract
Metabolites of a G protein-coupled receptor modulator containing 1,2,4-oxadiazole and piperazine substructures were identified in vitro in human, rat, and dog hepatocyte incubates and in vivo in rat plasma, bile, urine, and feces by using 14C-radiolabeled parent compound. Exposure coverage for the major circulating metabolites in humans at steady state and in preclinical species used in drug safety assessments was determined by using pooled plasma samples collected from a human multiple ascending dose study and a 3-month rat toxicokinetic study. Metabolites M1 and M2, which were formed by opening of the 1,2,4-oxadiazole ring, were observed as major metabolites both in vitro and in vivo across species. The carboxylic acid metabolite M2 was presumably formed through reductive N-O bond cleavage of the oxadiazole ring and subsequent hydrolysis. However, the mechanism for the formation of the unusual N-cyanoamide metabolite M1 remains uncertain. Neither M1 nor M2 had any target activity, as did parent drug P. In rat bile, rearranged Cys-piperazine and Gly-Cys-piperazine adducts, involving the formation of a five-membered heteroaromatic imidazole derivative from a six-membered piperazine ring, were observed as minor metabolites. These findings support a previously reported mechanism regarding glutathione detoxification for piperazine bioactivation products.Keywords
This publication has 22 references indexed in Scilit:
- From definition to implementation: a cross-industry perspective of past, current and future MIST strategiesXenobiotica, 2011
- Species Differences in the Biotransformation of an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist: The Effects of Distinct Glucuronide Metabolites on Overall Compound DispositionDrug Metabolism and Disposition, 2009
- Biotransformation of an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist in Sprague-Dawley Rats and the Dispositional Characterization of Its N-Carbamoyl Glucuronide MetaboliteDrug Metabolism and Disposition, 2009
- Approaches to the Assessment of Stable and Chemically Reactive Drug Metabolites in Early Clinical TrialsChemical Research in Toxicology, 2009
- An algorithm for thorough background subtraction from high‐resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urineJournal of Mass Spectrometry, 2008
- An algorithm for thorough background subtraction from high‐resolution LC/MS data: application for detection of glutathione‐trapped reactive metabolitesJournal of Mass Spectrometry, 2008
- Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and DogsDrug Metabolism and Disposition, 2007
- Metabolic Aromatization ofN-Alkyl-1,2,3,4-Tetrahydroquinoline Substructures to Quinolinium by Human Liver Microsomes and Horseradish PeroxidaseDrug Metabolism and Disposition, 2006
- Interspeciesin vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560Journal of Mass Spectrometry, 2006
- Metabolic Studies withTrans-5-Amino-3-[2-(5-Nitro-2-Furyl)Vinyl]-1,2,4-[5-14C]Oxadiazole (SQ 18,506): 1. Reductive Cleavage of the 1, 2, 4-oxadiazole ringXenobiotica, 1973